Seeking Alpha

Erasca, Inc.: Carving A Different Niche In RAS Signaling

Erasca, Inc. focuses on developing novel targeted therapies for solid tumors, particularly through the RAS/MAP kinase pathway, with a promising yet early-stage pipeline. The company’s lead program, ...
BioWorld

BAY-293 shows synergy with MAP kinase pathway inhibitors in human melanoma cell lines

Researchers from Medical University Vienna presented data from a study that aimed to identify possible synergism between the novel son of sevenless (SOS) inhibitor BAY-293 and B-Raf or/and MEK1/2 ...
ascopubs.org

Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers

NOTE. P < .00357 represents statistical significance after the Bonferroni correction. Abbreviations: MAPK, mitogen-activated protein kinase; NA, unable to be calculated; NR, not reached; OS, overall ...
Medscape

First Evidence: Targeted Melanoma Therapy May Change the Landscape of Treatment

Raf kinases are components of the MAP kinase pathway, a signal transduc-tion pathway that normally controls cell growth and division downstream of activated cell surface growth factor receptors. RAF1, ...